Ignite Creation Date:
2024-05-06 @ 6:02 PM
Last Modification Date:
2024-10-26 @ 2:40 PM
Study NCT ID:
NCT05520684
Status:
UNKNOWN
Last Update Posted:
2022-09-01
First Post:
2022-08-26
Brief Title:
Asymptomatic Bacteriuria Urinalysis Abnormality at the Initiation of SGLT2 Inhibitors and UTI Risk
Sponsor:
Trabzon Arakli Bayram Halil Public Hospital
Organization:
Trabzon Arakli Bayram Halil Public Hospital
Study Overview
Official Title:
Urinary Tract Infection Risk in Women With Asymptomatic Bacteriuria or Urinalysis Abnormality at the Initiation of SGLT2 Inhibitors
Status:
UNKNOWN
Status Verified Date:
2022-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The SGLT2 inhibitors have changed the treatment of type 2 diabetes mellitus in recent years especially in patients with cardiovascular or renal disease However the association between SGLT2 inhibitors and urinary tract infection UTI risk is controversial Moreover it is not known whether asymptomatic bacteriuria or urinalysis abnormality at the initiation of SGLT2 inhibitors are risk factors for UTI in women There is not enough data to recommend or not to recommend for performing urinalysis or urine culture test before initiation of SGLT2 inhibitors The aim of the study is to investigate the effect of asymptomatic bacteriuria or urinalysis abnormality at the initiation of SGLT2 inhibitors on UTI risk in a prospective cohort of women with type 2 diabetes mellitus
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None